Teva Pharmaceutical Industries (NYSE:TEVA) Research Coverage Started at Scotiabank

Scotiabank assumed coverage on shares of Teva Pharmaceutical Industries (NYSE:TEVA) in a research note released on Friday, Marketbeat Ratings reports. The firm issued a sector outperform rating and a $35.00 target price on the stock.

A number of other research firms have also weighed in on TEVA. Wall Street Zen upgraded shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research report on Saturday, October 11th. UBS Group lifted their target price on shares of Teva Pharmaceutical Industries from $23.00 to $26.00 and gave the company a “buy” rating in a report on Wednesday, September 24th. JPMorgan Chase & Co. increased their price target on shares of Teva Pharmaceutical Industries from $26.00 to $28.00 and gave the stock an “overweight” rating in a report on Thursday, November 6th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a report on Wednesday, October 8th. Two analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Buy” and an average target price of $27.00.

Teva Pharmaceutical Industries Stock Up 0.1%

Teva Pharmaceutical Industries stock opened at $28.45 on Friday. The stock has a 50 day moving average of $22.48 and a two-hundred day moving average of $19.20. Teva Pharmaceutical Industries has a twelve month low of $12.47 and a twelve month high of $28.68. The stock has a market capitalization of $32.63 billion, a price-to-earnings ratio of 47.42, a PEG ratio of 1.53 and a beta of 0.66. The company has a current ratio of 1.11, a quick ratio of 0.82 and a debt-to-equity ratio of 2.31.

Insider Buying and Selling at Teva Pharmaceutical Industries

In related news, Director Roberto Mignone sold 200,000 shares of the firm’s stock in a transaction that occurred on Thursday, November 6th. The stock was sold at an average price of $24.11, for a total value of $4,822,000.00. Following the completion of the transaction, the director directly owned 495,000 shares of the company’s stock, valued at $11,934,450. This trade represents a 28.78% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.55% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. Harel Insurance Investments & Financial Services Ltd. boosted its position in shares of Teva Pharmaceutical Industries by 51.4% in the 2nd quarter. Harel Insurance Investments & Financial Services Ltd. now owns 33,390,327 shares of the company’s stock worth $559,622,000 after buying an additional 11,334,780 shares in the last quarter. Menora Mivtachim Holdings LTD. lifted its holdings in shares of Teva Pharmaceutical Industries by 31.9% in the second quarter. Menora Mivtachim Holdings LTD. now owns 38,493,294 shares of the company’s stock valued at $645,148,000 after purchasing an additional 9,303,978 shares in the last quarter. Phoenix Financial Ltd. grew its position in shares of Teva Pharmaceutical Industries by 31.7% in the second quarter. Phoenix Financial Ltd. now owns 37,761,444 shares of the company’s stock valued at $632,882,000 after purchasing an additional 9,094,372 shares during the last quarter. Soundwatch Capital LLC purchased a new position in shares of Teva Pharmaceutical Industries during the 2nd quarter worth approximately $143,533,000. Finally, Wellington Management Group LLP raised its position in shares of Teva Pharmaceutical Industries by 39,228.4% during the 3rd quarter. Wellington Management Group LLP now owns 6,895,838 shares of the company’s stock worth $139,296,000 after purchasing an additional 6,878,304 shares during the last quarter. Hedge funds and other institutional investors own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.